Mesothelioma Life Expectancy + Survival Rates

Quick Answer

Mesothelioma median survival is 12-21 months without treatment. With multimodal treatment (surgery + chemotherapy + radiation), selected patients survive 2-5 years. Peritoneal mesothelioma treated with cytoreductive surgery + HIPEC has the best prognosis — selected patients survive 5+ years.

Mesothelioma life expectancy varies significantly by: (1) location (pleural vs peritoneal), (2) cell type (epithelioid vs sarcomatoid vs biphasic), (3) stage at diagnosis, (4) age and overall health, (5) treatment received.

Median Survival by Mesothelioma Type

• Pleural mesothelioma (75-80% of cases): median survival 12-21 months untreated; 16-24 months with chemotherapy; selected patients receiving multimodal treatment (surgery + chemo + radiation) survive 2-5 years.
• Peritoneal mesothelioma (10-20%): selected patients receiving cytoreductive surgery + HIPEC at high-volume centers achieve median survival 5+ years; some studies report 10+ year survival in selected cohorts.
• Pericardial mesothelioma (~1%): median survival under 12 months — limited treatment options.

Survival by Cell Type

• Epithelioid (60-70%): best prognosis — median 12-24 months with treatment
• Biphasic (20-30%): mixed — median 8-15 months
• Sarcomatoid (10-20%): worst prognosis — median often under 6 months

Recent Treatment Advances

**Immunotherapy**: Nivolumab + ipilimumab combination (Opdivo + Yervoy) was FDA-approved for first-line mesothelioma in 2020 — extends median survival to 18+ months in clinical trials, especially effective in sarcomatoid and biphasic patients (previously treatment-resistant).

**Multimodal treatment**: combining surgery (extrapleural pneumonectomy or pleurectomy/decortication) with chemotherapy and radiation has shown extended survival in selected patients — some 5+ year survivors.

**HIPEC for peritoneal**: cytoreductive surgery + heated intraperitoneal chemotherapy at high-volume centers (Washington Hospital Center, Mt Sinai, MD Anderson, etc.) has dramatically improved peritoneal mesothelioma prognosis.